A GFR of 48 is Stage 3a Chronic Kidney Disease
A GFR of 48 mL/min/1.73 m² classifies as Stage 3a chronic kidney disease (CKD), defined by the range of 45-59 mL/min/1.73 m². 1
GFR-Based Classification
- The National Kidney Foundation KDOQI guidelines establish that Stage 3a CKD encompasses GFR values between 45-59 mL/min/1.73 m², which includes your patient's GFR of 48 2, 1
- This represents loss of approximately half or more of normal adult kidney function, and below a GFR of 60, the prevalence of CKD complications increases significantly 2
- Stage 3 was subdivided into 3a and 3b by KDIGO and KDOQI because mortality and adverse outcome risks vary substantially between these subgroups, making this distinction clinically critical 3, 1
Complete Risk Assessment Required
You cannot fully assess this patient's risk or determine appropriate management frequency with GFR alone—you must also measure albuminuria. 1, 4
- The complete CKD classification requires both GFR category AND albuminuria measurement using the albumin-to-creatinine ratio (ACR) 1, 4
- Albuminuria categories are: A1 (<30 mg/g), A2 (30-299 mg/g), and A3 (≥300 mg/g) 1, 4
- At GFR 48 with normal albuminuria (A1), the patient is classified as G3a/A1, representing moderate risk requiring annual monitoring 1
- If albuminuria is elevated to A2 or A3, risk increases substantially to orange or red zones, requiring monitoring twice to three times yearly and consideration for nephrology referral 1
Clinical Management at Stage 3a
Immediate actions required:
- Adjust doses of all renally cleared medications at this GFR level 1
- Prescribe ACE inhibitors or ARBs if the patient has diabetes with hypertension and any degree of albuminuria 1
- Refer to nephrology if severely increased albuminuria (A3 category) is present, regardless of GFR being in the 3a range 1, 4
- Monitor both eGFR and urine albumin-to-creatinine ratio at minimum annually for G3a/A1 patients 1
Prognostic Implications
- Stage 3a patients without elevated albuminuria have relatively preserved prognosis compared to Stage 3b-5, with research showing that Stage 3a alone does not significantly increase mortality risk compared to Stages 1-2 (HR 1.11, not statistically significant) 5
- However, Stage 3b and beyond show dramatically increased risks (HR 1.66-2.75 for mortality) 5
- Approximately 48% of Stage 3 CKD patients do not progress over 10 years, but Stage 3b patients have nearly 3-fold higher risk of progression compared to Stage 3a (HR 2.99) 6
- Delayed diagnosis is associated with elevated risk of progression to Stage 4/5 (HR 1.40 per year of delay) and kidney failure (HR 1.63) 7
Critical Diagnostic Caveat
A single GFR measurement of 48 does not establish chronic kidney disease. The diagnosis requires abnormalities to be present for >3 months, so you must confirm with repeat testing at least 3 months apart before labeling this as CKD 1, 8